Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study

This publication has 12 references indexed in Scilit:

• Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
  Archives of internal medicine (1960), 2002
• Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease
  JAMA, 2000
• Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
  Published by Elsevier ,2000
• Clinical trial experience with extended-release niacin (niaspan): dose-escalation study
  The American Journal of Cardiology, 1998
• Efficacy and safety of an extended-release niacin (niaspan): a long-term study
  The American Journal of Cardiology, 1998
• Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
  Metabolism, 1998
• Conference Report on Stroke Mortality in the Southeastern United States
  Hypertension, 1998
• Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
  The American Journal of Cardiology, 1994
• Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results
  Archives of internal medicine (1960), 1991
• A Patient Education Program to Improve Adherence Rates with Antituberculosis Drug Regimens
  Health Education Quarterly, 1990